Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

Medically reviewed by Smita Patel, DO Formerly known as Lou Gehrig’s disease, amyotrophic lateral sclerosis is now commonly referred to as “ALS.” It is a neurological disease that affects motor ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Its lead product is NeuroNata-R (lenzumestrocel), the world’s first stem cell-based therapy for amyotrophic lateral sclerosis (ALS ... mixing with cerebro-spinal fluid collected from the ...

Amyotrophic Lateral Sclerosis [ALS] is a type of disorder characterized as a progressive disorder where the nerve cells of the brain and spinal cord ... to evaluate a change in disease severity ...

With the hold lifted, Amylyx can begin screening and enrolling for its Phase 1 LUMINA trial, which will test AMX0114 in ALS ...

The ALS Association will host its second ALS Nexus conference in August, with the goal of making the disease a livable one ...

(Reuters) -Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...

The FDA has granted approval for Zydus to proceed with the Phase II(b) trial of Usnoflast for amyotrophic lateral sclerosis (ALS) treatment.